Barclays PLC 89bio, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 354,088 shares of ETNB stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
354,088
Previous 543,552
34.86%
Holding current value
$2.8 Million
Previous $6.07 Million
32.12%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ETNB
# of Institutions
165Shares Held
89.1MCall Options Held
584KPut Options Held
1.17M-
Janus Henderson Group PLC London, X012.6MShares$99.6 Million0.08% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$58.3 Million1.38% of portfolio
-
Black Rock Inc. New York, NY6.64MShares$52.4 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.3MShares$49.8 Million3.14% of portfolio
-
State Street Corp Boston, MA5.54MShares$43.8 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $367M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...